SaliTect is developing a chairside AI diagnostic system that delivers an instant, non-invasive periodontal risk score — built for the dental clinic, designed to prevent the treatments that cost 35× more.
The Problem
Chronic periodontitis affects 40% of Swedish adults. Current clinical tools detect it only after irreversible tissue damage has occurred. Prevention — the affordable option — is structurally blocked by the diagnostics available today.
Rapid tests track one molecule in saliva — a fluid too biologically variable for single-point measurement. Results are unreliable in real clinical conditions.
Physical probing measures past damage, not current disease activity. By the time a diagnosis is confirmed, prevention is no longer an option.
Confirmatory lab tests take days to return results. The decision window inside the patient visit closes long before answers arrive.
Untreated periodontitis is independently linked to diabetes, cardiovascular disease, and adverse pregnancy outcomes — creating a diagnostic gap that becomes a systemic cost.
How It Works
The E-Tongue platform combines a multi-electrode biosensor array, a portable analyzer unit, and an AI clinical decision support interface. Together, they deliver an actionable risk score within minutes — without a laboratory, without a painful probe.
The patient provides a small saliva sample at the chairside. Non-invasive, sterile, and completed in seconds — no laboratory logistics required.
The sample is loaded into a sterile, single-use sensor cartridge — a modular, low-cost disposable that contains the multi-electrode array.
The cartridge is inserted into the compact chairside analyzer, which captures a complex electrochemical fingerprint across multiple electrode materials — overcoming the biological noise that defeats single-biomarker tests.
The companion app translates raw biosensor data into an AI-generated risk score, confidence level, and clinical recommendation — written directly into the patient record for immediate action.
Market Opportunity
~3,000 clinics in Sweden, up to 200,000 across the EU. The platform creates a new, billable same-visit diagnostic service that fits inside the existing consultation flow with minimal implementation cost.
The same electrode array and AI engine can be retrained for systemic disease screening and extended beyond medicine into industrial fluid quality control. One hardware platform, multiple markets — with every validated study strengthening a proprietary dataset that compounds over time.
Competitive Position
Current periodontal diagnostics force a choice between accuracy and speed. The E-Tongue platform resolves the trade-off with pattern-recognition AI applied to a multi-electrode fingerprint.
| Dimension | E-Tongue (SaliTect) | PerioSafe® (Dentognostics) | MyPerioPath® (OralDNA) | Oral Genome |
|---|---|---|---|---|
| Core technology | Multi-electrode array + AI | Single biomarker (LFA) | PCR / DNA sequencing | LFA, 7 biomarkers + AI |
| Time to result | ✓ Minutes, chairside | ~5 minutes | 5–10 days | Under 15 minutes |
| Variability handling | ✓ AI normalizes noise | ✗ Fails if marker diluted | Lab-controlled only | Partial (LFA-bound) |
| Lab required | ✓ No | ✓ No | ✗ Yes | ✓ No |
| Clinic revenue model | ✓ High-volume screening | Niche / ad-hoc | Low-volume specialty | Recently launched (TBE) |
| Platform expandability | ✓ Multi-indication | ✗ Single indication | ✗ Single indication | Limited |
Team
Founded at Malmö University with a deliberate mix of electrochemical sensing, machine learning, clinical periodontology, and interaction design — every core discipline needed to take E-Tongue from lab to market is represented in-house.
Partners & Advisors
Backed by institutional research partners, a clinical validation network spanning two universities, regulatory advisory, and incubator support — covering the full path from early-stage development to market entry.
Get in touch
Whether you represent a dental network, a diagnostics company, a research institution, or an investment fund, we want to hear from you. SaliTect is actively seeking clinical sites, industry collaborators, and investors aligned with medtech and preventive care.
Watch
